Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

AZN.LN : 12,350.000 (+0.26%)
AZN : 77.43 (+0.32%)
GSK.LN : 1,807.750 (-0.12%)
GSK : 45.17 (+0.22%)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

These companies are close to launching new products that could supercharge revenue.

LLY : 757.70 (-0.30%)
PFE : 28.44 (+1.54%)
GSK.LN : 1,807.750 (-0.12%)
MRNA : 125.67 (+7.13%)
VRTX : 429.93 (+1.69%)
Babies should get recently approved drug for RSV, CDC says

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

PFE : 28.44 (+1.54%)
GSK.LN : 1,807.750 (-0.12%)
GSK : 45.17 (+0.22%)
AZN.LN : 12,350.000 (+0.26%)
AZN : 77.43 (+0.32%)
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BLU : 14.74 (unch)
GSK.LN : 1,807.750 (-0.12%)
GSK : 45.17 (+0.22%)
BLU.TO : 19.48 (-0.10%)
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

SGEN : 228.74 (-0.07%)
AZN : 77.43 (+0.32%)
IMGN : 31.23 (unch)
GSK : 45.17 (+0.22%)
GSK.LN : 1,807.750 (-0.12%)
PFE : 28.44 (+1.54%)
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

FOSUF : 0.5350 (+1.94%)
FOSUY : 14.5300 (+1.25%)
GSK.LN : 1,807.750 (-0.12%)
GSK : 45.17 (+0.22%)
JNJ : 151.22 (+0.87%)
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...

BLU : 14.74 (unch)
GSK : 45.17 (+0.22%)
GSK.LN : 1,807.750 (-0.12%)
BLU.TO : 19.48 (-0.10%)
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging

While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat

IBM : 167.56 (+0.25%)
GOOG : 170.90 (+0.36%)
GOOGL : 169.14 (+0.29%)
GM : 45.17 (-0.09%)
GMM-U.TO : 43.32 (-1.23%)
GSK : 45.17 (+0.22%)
GSK.LN : 1,807.750 (-0.12%)
MSFT : 413.72 (-0.25%)
WWE : 100.65 (+2.65%)
Schrodinger is an AI-Powered Drug Discovery Developer to Watch

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

SDGR : 23.18 (+1.98%)
AZN.LN : 12,350.000 (+0.26%)
AZN : 77.43 (+0.32%)
AZNCF : 155.8400 (-0.11%)
LLY : 757.70 (-0.30%)
GSK : 45.17 (+0.22%)
GSK.LN : 1,807.750 (-0.12%)
ON : 72.33 (+2.65%)
PFE : 28.44 (+1.54%)
MRK : 129.29 (-0.59%)
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive 12-month findings from the SOLAR study. SOLAR is the first head-to-head,...

GSK.LN : 1,807.750 (-0.12%)
PFE : 28.44 (+1.54%)

Barchart Exclusives

1 'Strong Buy' Dividend Stock to Buy and Hold
Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar